| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
1 Department of Molecular Genetics, Lerner Research Institute, Cleveland Clinic Foundation and Departments of 2 Genetics and 3 Radiation Oncology and Pharmacology, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, Ohio
Requests for reprints: Mark W. Jackson, Department of Molecular Genetics, Lerner Research Institute/NC20, Cleveland Clinic Foundation, 9500, Euclid Avenue, Cleveland, OH 44195. Phone: 216-368-5674; Fax: 216-368-8919; E-mail: mwj7{at}cwru.edu.
Hdm2 and HdmX coordinately regulate the stability and function of p53. Each is overexpressed in subsets of many different types of malignancy, and most of these subsets maintain wild-type p53. Nutlins, newly discovered small-molecule inhibitors of the Hdm2-p53 interaction, offer a novel strategy for therapy of tumors with wild-type p53. We now show that Nutlin-3 efficiently induces apoptosis and diminishes long-term survival of human fibroblasts transformed in vitro by Hdm2 but not HdmX. The resistance of cells overexpressing HdmX to Nutlin-3 is due to its inability to disrupt the p53-HdmX interaction, resulting in continued suppression of p53 activity. Although HdmX overexpression yielded cells resistant to Nutlin-3, ablation of HdmX expression by short hairpin RNA sensitized tumor cells to Nutlin-3–mediated cell death or arrest. Furthermore, deletion of the COOH-terminal RING finger domain of HdmX completely reversed the resistance to Nutlin-3, probably reflecting the requirement of the RING finger for interaction with Hdm2. Thus, the relative abundance of Hdm2 and HdmX and the specificity of Nutlin-3 for Hdm2 influence the sensitivity of cells to p53-dependent apoptosis or arrest in response to Nutlin-3. Our findings establish Hdm2 and HdmX as independent therapeutic targets with respect to reactivating wild-type p53 as a means for cancer therapy. (Cancer Res 2006; 66(6): 3169-76)
This article has been cited by other articles:
|
|
 |
|
  J. Phan, Z. Li, A. Kasprzak, B. Li, S. Sebti, W. Guida, E. Schonbrunn, and J. Chen Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX J. Biol. Chem., January 15, 2010; 285(3): 2174 - 2183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Du, J. Wu, E. M. Walsh, Y. Zhang, C. Y. Chen, and Z.-X. J. Xiao Nutlin-3 Affects Expression and Function of Retinoblastoma Protein: ROLE OF RETINOBLASTOMA PROTEIN IN CELLULAR RESPONSE TO NUTLIN-3 J. Biol. Chem., September 25, 2009; 284(39): 26315 - 26321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rinaldo, A. Prodosmo, F. Siepi, A. Moncada, A. Sacchi, G. Selivanova, and S. Soddu HIPK2 Regulation by MDM2 Determines Tumor Cell Response to the p53-Reactivating Drugs Nutlin-3 and RITA Cancer Res., August 1, 2009; 69(15): 6241 - 6248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kallen, A. Goepfert, A. Blechschmidt, A. Izaac, M. Geiser, G. Tavares, P. Ramage, P. Furet, K. Masuya, and J. Lisztwan Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes J. Biol. Chem., March 27, 2009; 284(13): 8812 - 8821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Forte and M. A. Luftig MDM2-Dependent Inhibition of p53 Is Required for Epstein-Barr Virus B-Cell Growth Transformation and Infected-Cell Survival J. Virol., March 15, 2009; 83(6): 2491 - 2499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tabe, D. Sebasigari, L. Jin, M. Rudelius, T. Davies-Hill, K. Miyake, T. Miida, S. Pittaluga, and M. Raffeld MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma Clin. Cancer Res., February 1, 2009; 15(3): 933 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wade and G. M. Wahl Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry? Mol. Cancer Res., January 1, 2009; 7(1): 1 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Bassett, W. Wang, F. Rastinejad, and W. S. El-Deiry Structural and Functional Basis for Therapeutic Modulation of p53 Signaling Clin. Cancer Res., October 15, 2008; 14(20): 6376 - 6386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shangary and S. Wang Targeting the MDM2-p53 Interaction for Cancer Therapy Clin. Cancer Res., September 1, 2008; 14(17): 5318 - 5324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shangary, D. Qin, D. McEachern, M. Liu, R. S. Miller, S. Qiu, Z. Nikolovska-Coleska, K. Ding, G. Wang, J. Chen, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition PNAS, March 11, 2008; 105(10): 3933 - 3938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-C. L. Chang, R. A. Coudry, M. L. Clapper, X. Zhang, K.-L. Williams, C. S. Spittle, T. Li, and H. S. Cooper Loss of p53 enhances the induction of colitis-associated neoplasia by dextran sulfate sodium Carcinogenesis, November 1, 2007; 28(11): 2375 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Kan, J. T. Patton, G. R. Stark, and M. W. Jackson p53-Mediated Growth Suppression in Response to Nutlin-3 in Cyclin D1 Transformed Cells Occurs Independently of p21 Cancer Res., October 15, 2007; 67(20): 9862 - 9868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Hu, D. M. Gilkes, and J. Chen Efficient p53 Activation and Apoptosis by Simultaneous Disruption of Binding to MDM2 and MDMX Cancer Res., September 15, 2007; 67(18): 8810 - 8817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. V. Wang, M. Wade, E. Wong, Y.-C. Li, L. W. Rodewald, and G. M. Wahl Quantitative analyses reveal the importance of regulated Hdmx degradation for P53 activation PNAS, July 24, 2007; 104(30): 12365 - 12370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Bentle, K. E. Reinicke, Y. Dong, E. A. Bey, and D. A. Boothman Nonhomologous End Joining Is Essential for Cellular Resistance to the Novel Antitumor Agent, {beta}-Lapachone Cancer Res., July 15, 2007; 67(14): 6936 - 6945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C.A. Graat, J. E. Carette, F. H.E. Schagen, L. T. Vassilev, W. R. Gerritsen, G. J.L. Kaspers, P. I.J.M. Wuisman, and V. W. van Beusechem Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53 Mol. Cancer Ther., May 1, 2007; 6(5): 1552 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Petre, S.-H. Sin, and D. P. Dittmer Functional p53 Signaling in Kaposi's Sarcoma-Associated Herpesvirus Lymphomas: Implications for Therapy J. Virol., February 15, 2007; 81(4): 1912 - 1922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. W. Marine, M. A. Dyer, and A. G. Jochemsen MDMX: from bench to bedside J. Cell Sci., February 1, 2007; 120(3): 371 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jiang, N. Pabla, R. F. Murphy, T. Yang, X.-M. Yin, K. Degenhardt, E. White, and Z. Dong Nutlin-3 Protects Kidney Cells during Cisplatin Therapy by Suppressing Bax/Bak Activation J. Biol. Chem., January 26, 2007; 282(4): 2636 - 2645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. LaRusch, M. W. Jackson, J. D. Dunbar, R. S. Warren, D. B. Donner, and L. D. Mayo Nutlin3 Blocks Vascular Endothelial Growth Factor Induction by Preventing the Interaction between Hypoxia Inducible Factor 1{alpha} and Hdm2 Cancer Res., January 15, 2007; 67(2): 450 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Hu, D. M. Gilkes, B. Farooqi, S. M. Sebti, and J. Chen MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin J. Biol. Chem., November 3, 2006; 281(44): 33030 - 33035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wade, E. T. Wong, M. Tang, J. M. Stommel, and G. M. Wahl Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells J. Biol. Chem., November 3, 2006; 281(44): 33036 - 33044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Jackson, L. E. Patt, G. A. LaRusch, D. B. Donner, G. R. Stark, and L. D. Mayo Hdm2 Nuclear Export, Regulated by Insulin-like Growth Factor-I/MAPK/p90Rsk Signaling, Mediates the Transformation of Human Cells J. Biol. Chem., June 16, 2006; 281(24): 16814 - 16820. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
